{"id":31148,"date":"2020-06-09T09:38:03","date_gmt":"2020-06-09T09:38:03","guid":{"rendered":"https:\/\/www.gkseries.com\/blog\/?p=31148"},"modified":"2020-10-14T09:39:50","modified_gmt":"2020-10-14T09:39:50","slug":"csirs-anti-cancer-drug-iiim-290-went-into-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.gkseries.com\/blog\/csirs-anti-cancer-drug-iiim-290-went-into-clinical-trial\/","title":{"rendered":"CSIR\u2019s anti-cancer drug IIIM-290 went into clinical trial"},"content":{"rendered":"\n<p>CSIR constituent lab, CSIR-Indian Institute of Integrative Medicine (IIIM) Jammu, has received Investigational New Drug (IND) approval from New Drugs Division of Central Drugs Standard Control Organisation (CDSCO) for a potent anti-cancer, new chemical entity (NCE) effective against pancreatic cancer after successful completion of preclinical development and IND submission.<\/p>\n\n\n\n<p>The proposed clinical trial will pave the way for CSIR-IIIM to conduct the clinical trial of the important drug candidate IIIM-290 in pancreatic cancer patients.<\/p>\n\n\n\n<p>It is also aimed to assess the safety, tolerability, and exposure of the compound in humans along with the early efficacy indicators in pancreatic cancer patients.<\/p>\n\n\n\n<p>The drug IIIM-290 was discovered and developed at the natural-products driven drug discovery program of CSIR-IIIM.<\/p>\n\n\n\n<p>The drug candidate IIIM-290 showed excellent pharmacokinetics, oral bioavailability and potent anticancer activity in a number of animal xenograft models, with the best activity against the pancreatic cancer model.<\/p>\n\n\n\n<p>Pancreatic cancer, currently, ranks 12th among the most common cancers in the world. But it stands as the 4th leading cause of cancer-related deaths.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CSIR constituent lab, CSIR-Indian Institute of Integrative Medicine (IIIM) Jammu, has received Investigational New Drug (IND) approval from New Drugs Division of Central Drugs Standard Control Organisation (CDSCO) for a potent anti-cancer, new chemical entity (NCE) effective against pancreatic cancer after successful completion of preclinical development and IND submission. The proposed clinical trial will pave [&hellip;]<\/p>\n","protected":false},"author":404,"featured_media":31149,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1174],"tags":[68],"class_list":["post-31148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-current-affairs-june-2020","tag-science-technology-current-affairs"],"_links":{"self":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/31148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/users\/404"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/comments?post=31148"}],"version-history":[{"count":1,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/31148\/revisions"}],"predecessor-version":[{"id":31150,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/posts\/31148\/revisions\/31150"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media\/31149"}],"wp:attachment":[{"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/media?parent=31148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/categories?post=31148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gkseries.com\/blog\/wp-json\/wp\/v2\/tags?post=31148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}